Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals H1-FY27 Earnings Highlights and Growth Roadmap

For H1-FY27, Remus Pharmaceuticals posted consolidated revenue of INR 614.12 crores (up 53% YoY), EBITDA of INR 29.93 crores (margin 5%), and PAT of INR

Remus Pharmaceuticals H1-FY27 Earnings Highlights and Growth Roadmap

Remus Pharmaceuticals Ltd 路 Transcript 路 06 Nov 2026, 7:10 pm

Remus Pharmaceuticals H1-FY27 Earnings Highlights and Growth Roadmap For H1-FY27, Remus Pharmaceuticals posted consolidated revenue of INR 614.12 crores (up 53% YoY), EBITDA of INR 29.93 crores (margin 5%), and PAT of INR 24.66 crores (up 14% YoY). Standalone revenue rose 32% YoY to INR 62 crores with a 35% EBITDA margin and INR 19 crores PAT (up 57% YoY). The Board approved an interim dividend of INR 1 per share. Management targets higher H2 growth, driven by Latin American expansion, GLP-1 (Semaglutide) commercialization, biosimilars, and expected migration to the main board.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements